Clearside Biomedical is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. The company’s proprietary SCS Microinjector® targeting the suprachoroidal space (SCS®) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs.

Using the company’s suprachoroidal injection technology that can be used in conjunction with proprietary formulations of existing drugs, novel therapies, as well as future therapeurtic innovastions, the company believes that it has created a broad therapeutic platform for developing product candidates to treat serious eye diseases.

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey.

Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis.

Founded based on the research of Professors Noriko Koizumi and Naoki Okumura at Doshisha University in Kyoto, Japan, ActualEyes is a Japan-based clinical stage biotech company committed to the research and development of both cell therapy and pharmacological treatments for corneal endothelial dysfunction, including Fuchs endothelial corneal dystrophy (FECD) and bullous keratopathy. 

Olympic Ophthalmics, Inc. is a medical technology company pioneering patient-focused treatments for ophthalmic diseases using neuromodulation. The company is based in Issaquah, Washington, and primarily backed by BioStar Capital, a physician-led, strategic value-add investment firm focused on accelerating value creation for transformational medical device and connected health technologies. 

LKS Faculty of Medicine at the University of Hong Kong (HKUMed) is the oldest medical school in Hong Kong with a history of more than 100 years. It is a world-renowned pioneer in medical education, training and research. The Department of Ophthalmology, HKMed is dedicated to improving the level of scientific research. Its current research projects include: conducting a multi-center clinical treatment trial for retinal macular disease; developing ocular gene therapy to protect the optic nerve of glaucoma patients; and innovating treatment paradigms , to improve the visual acuity of cataract patients after surgery.